qr-421a
Nucleic acidexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Mar 6, 2019 (NCT03780257)
Timeline
Indications
Mechanism of action
- UsherinINHIBITOR
USH2A inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06627179 | Phase 2 | Dec 31, 2024 | Laboratoires Thea, Sepul Bio |
| NCT05176717 | Phase 2/Phase 3 (Phase 3) | Dec 15, 2021 | ProQR Therapeutics |
| NCT05158296 | Phase 2/Phase 3 (Phase 3) | Dec 8, 2021 | ProQR Therapeutics |
| NCT05085964 | Phase 2 | Sep 13, 2021 | ProQR Therapeutics |
| NCT03780257 | Phase 1/Phase 2 (Phase 2) | Mar 6, 2019 | ProQR Therapeutics |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ProQR Therapeutics | For profit | 4 | 4 | 2 | 2019 |
| Laboratoires Thea | For profit | 1 | 1 | 1 | 2024 |
| Sepul Bio | For profit | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1